Wiss, F.M. et al. (2024) “Associations between (pharmaco-)genetic markers and postoperative pain after inguinal hernia repair – a prospective study protocol”, BMC Medical Genomics, 17(1). Available at: 10.1186/s12920-024-02064-6.   

Wiss, F.M. et al. (2024) “Overcoming Barriers: Strategies for Implementing Pharmacist-Led Pharmacogenetic Services in Swiss Clinical Practice”, Genes, 15(7). Available at: 10.3390/genes15070862.   

Stäuble, C.K. et al. (2024) “A Clinical Practice Perspective on the Evaluation of OATP1B1‐associated Drug Interactions”, Clinical Pharmacology & Therapeutics [Preprint]. Available at: 10.1002/cpt.3247.   

Wiss, F.M. et al. (2024) “Recurrent high creatine kinase levels under clozapine treatment - a case report assessing a suspected adverse drug reaction”, Frontiers in Psychiatry, 15. Available at: 10.3389/fpsyt.2024.1397876.   

Wiss, F.M. et al. (2023) “Pharmacogenetic Analysis Enables Optimization of Pain Therapy: A Case Report of Ineffective Oxycodone Therapy”, Journal of Personalized Medicine, 13(5), p. 829. Available at: 10.3390/jpm13050829.   

Studer, H. et al. (2023) “The impact of pharmacist-led medication reconciliation and interprofessional ward rounds on drug-related problems at hospital discharge”, International Journal of Clinical Pharmacy, 45(1), pp. 117–125. Available at: 10.1007/s11096-022-01496-3.   

Bollinger, A. et al. (2023) “Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study”, Pharmacogenomics and Personalized Medicine, 16, pp. 693–706. Available at: 10.2147/PGPM.S415259.   

Stäuble, C.K. et al. (2021) “Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial”, Trials, 22(1), p. 919. Available at: 10.1186/s13063-021-05724-5.   

Stäuble, C.K. et al. (2021) “Pharmacogenetic-guided antidepressant selection as an opportunity for interprofessional collaboration: A case report”, Life, 11(7), p. 673. Available at: 10.3390/life11070673.   

Stäuble, C.K. et al. (2021) “Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying; CYP2D6; *4 Variants: A Case Report”, International Journal of Molecular Siences, 22(12), p. 6480. Available at: 10.3390/ijms22126480.   edoc

Jeiziner, C. et al. (2021) “Enriching medication review with a pharmacogenetic profile – a case of tamoxifen adverse drug reactions”, Pharmacogenomics and Personalized Medicine, 14, pp. 279–286. Available at: 10.2147/pgpm.s285807.   

Stäuble, C.K. et al. (2021) “Pharmacogenetics in Pharmaceutical Care-Piloting an Application-Oriented Blended Learning Concept”., Pharmacy (Basel, Switzerland), 9(3), p. 152. Available at: 10.3390/pharmacy9030152.   

Studer, H. et al. (2021) “Pharmaceutical Discharge Management: Implementation in Swiss Hospitals Compared to International Guidelines”., Pharmacy (Basel, Switzerland), 9(1), p. 33. Available at: 10.3390/pharmacy9010033.   

Imfeld-Isenegger, T.L. et al. (2021) “Detection and resolution of drug-related problems at hospital discharge focusing on information availability - a retrospective analysis”., Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen, 166, pp. 18–26. Available at: 10.1016/j.zefq.2021.08.004.   

Lampert, M.L. (2021) Medicines Management Optimisation by Structured Assessment in Integrated Care (A framework for research and development). Habilitation.   

Stäuble, C.K. et al. (2020) “Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B6*6 and CYP2C19*17 variants: A case report”, Pharmacogenomics, 21(16), pp. 1145–1150. Available at: 10.2217/pgs-2020-0087.   

Arnet, I. et al. (2020) “Lessons learned from three months of pharmaceutical-care digital-education at the University of Basel, Switzerland”, Senior Care Pharmacist, 35(11), pp. 479–481. Available at: 10.4140/tcp.n.2020.479.   

Studer, H. et al. (2020) “Clinical Pharmacy Activities in Swiss Hospitals: How Have They Evolved from 2013 to 2017?”, Pharmacy, 8(1), p. 19. Available at: 10.3390/pharmacy8010019.   edoc | Open Access

Maes, K.A. et al. (2019) “Dispensing of Prescribed Medicines in Swiss Community Pharmacies-Observed Counselling Activities”, Pharmacy, 7(1), pp. 1–16. Available at: 10.3390/pharmacy7010001.   edoc | Open Access

Stämpfli, D. et al. (2018) “Translation and validation of a tool to assess the impact of clinical pharmacists’ interventions”, International journal of clinical pharmacy, 41(1), pp. 56–64. Available at: 10.1007/s11096-018-0755-0.   edoc

Maes, K.A., Hersberger, K.E., Lampert, M.L. (2018) “Pharmaceutical interventions on prescribed medicines in community pharmacies: focus on patient-reported problems”, International journal of clinical pharmacy, 40(2), pp. 335–340. Available at: 10.1007/s11096-018-0595-y.   edoc

Stämpfli, D. et al. (2018) “Assessing the ability of the Drug-Associated Risk Tool (DART) questionnaire to stratify hospitalised older patients according to their risk of drug-related problems: a cross-sectional validation study”, BMJ open, 8(6), p. e021284. Available at: 10.1136/bmjopen-2017-021284.   edoc

Stämpfli, D. et al. (2018) “Contribution of Patient Interviews as Part of a Comprehensive Approach to the Identification of Drug-Related Problems on Geriatric Wards”, Drugs & aging, 35(7), pp. 665–675. Available at: 10.1007/s40266-018-0557-z.   edoc

Kaufmann, C.P. et al. (2018) “Drug-Associated Risk Tool: development and validation of a self-assessment questionnaire to screen for hospitalised patients at risk for drug-related problems”, BMJ Open, 8(3), p. e016610. Available at: 10.1136/bmjopen-2017-016610.   edoc | Open Access

Maes, K.A. et al. (2017) “Documentation of pharmaceutical care: Validation of an intervention oriented classification system”, Journal of Evaluation in Clinical Practice, 23(6), pp. 1425–1432. Available at: 10.1111/jep.12817.   edoc

Maes, K.A. et al. (2017) “Documentation of pharmaceutical care: development of an intervention oriented classification system”, International Journal of Clinical Pharmacy, 39(2), pp. 354–363. Available at: 10.1007/s11096-017-0442-6.   edoc

Kaufmann, C.P. et al. (2014) “Inappropriate prescribing : a systematic overview of published assessment tools”, European journal of clinical pharmacology, 70(1), pp. 1–11. Available at: 10.1007/s00228-013-1575-8.   edoc

Hersberger, K.E., Lampert, M.L., Bernnhardt, V. (2014) “Schlüsselkompetenzen Pharmazie”, in V. Heyse and M. Giger (eds.) Erfolgreich in die Zukunft. Schlüsselkompetenzen in Gesundheitsberufen. Konzepte und Praxismodelle für die Aus-, Weiter- und Fortbildung in Deutschland, Österreich und der Schweiz. Heidelberg: medhochzwei (Gesundheitsmarkt in der Praxis), pp. 239–267.   edoc

Mengiardi, S. et al. (2011) “Drug use problems with self-injected low-molecular-weight heparins in primary care”, European journal of clinical pharmacology, 67(2), pp. 109–20. Available at: 10.1007/s00228-010-0956-5.   edoc

Eichenberger, P.M. et al. (2010) “Classification of drug-related problems with new prescriptions using a modified PCNE classification system”, Pharmacy world & science, 32(3), pp. 362–72. Available at: 10.1007/s11096-010-9377-x.   edoc

Lampert, M.L., Kraehenbuehl, S., Hug, B.L. (2008) “Drug-related problems : evaluation of a classification system in the daily practice of a Swiss University Hospital”, Pharmacy world & science, 30(6), pp. 768–76. Available at: 10.1007/s11096-008-9213-8.   edoc | Open Access

Burri, E. et al. (2007) “Subtherapeutische Phenytoinspiegel infolge eines Medikationsfehlers”. (PRAXIS), pp. 687–92. Available at: 10.1024/1661-8157.96.17.687.   edoc

Lampert, M.L. et al. (2007) “Ungewöhlicher Wirkungsverlust von Oxcarbazepin”. (PRAXIS), pp. 1843–8. Available at: 10.1024/1661-8157.96.47.1843.   edoc

Kummer, O. et al. (2006) “Agranulozytose bei einem mit Metamizol und Clopidogrel behandelten Patienten”, PRAXIS, 95(45), pp. 1743–5; quiz 1746. Available at: 10.1024/1661-8157.95.45.1743.   edoc